COMPASS Pathways plc (NASDAQ:CMPS) Receives $18.83 Consensus Target Price from Analysts

COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $18.83.

Several equities analysts recently commented on CMPS shares. Canaccord Genuity Group reduced their price target on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Cantor Fitzgerald restated an "overweight" rating and set a $12.00 price objective on shares of COMPASS Pathways in a report on Tuesday, May 27th. HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of COMPASS Pathways in a report on Monday, May 12th. Finally, Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday, February 27th. They set a "buy" rating and a $11.00 price objective on the stock.

Institutional Investors Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently bought and sold shares of CMPS. Cerity Partners LLC bought a new stake in shares of COMPASS Pathways in the 1st quarter valued at approximately $29,000. GAMMA Investing LLC increased its holdings in shares of COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after acquiring an additional 5,003 shares during the last quarter. Ethos Financial Group LLC bought a new stake in shares of COMPASS Pathways in the 1st quarter valued at approximately $35,000. Flagship Harbor Advisors LLC increased its holdings in shares of COMPASS Pathways by 27.7% in the 1st quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after acquiring an additional 3,134 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in shares of COMPASS Pathways in the 1st quarter valued at approximately $41,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Up 5.7%

COMPASS Pathways stock traded up $0.25 during midday trading on Friday, hitting $4.64. 1,699,013 shares of the company were exchanged, compared to its average volume of 903,341. The company's fifty day moving average price is $3.94 and its 200-day moving average price is $3.88. The company has a market cap of $434.13 million, a PE ratio of -2.11 and a beta of 2.25. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a fifty-two week low of $2.49 and a fifty-two week high of $8.54.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.03. On average, research analysts predict that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.